Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma (NASDAQ:AMPH), Fresenius Medical Care (NYSE:FMS)

Iron deficiency anemia often goes undiagnosed due to vague symptoms

8-12-25-Uncovering The Hidden Symptoms Of Iron Deficiency INDIANAPOLIS (WISH)– Iron deficiency anemia, a common nutritional deficiency, often goes undiagnosed due to its vague symptoms, according to Dr. Mukul Singal from Innovative Hematology. Dr. Singal explains that symptoms such as fatigue, concentration issues and mood changes can easily be mistaken for stress, leading to a lack of proper diagnosis and treatment. “Iron deficiency initially m…

Why Is Amphastar Pharma Stock Soaring Tuesday? - Amphastar Pharma (NASDAQ:AMPH), Fresenius Medical Care (NYSE:FMS)

On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, previously referred to as AMP-002. Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). “We look …

Viatris receives FDA nod for generic Venofer injection

Iron sucrose injection is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

FDA approves first generic iron sucrose injection for iron deficiency anemia in CKD

FDA approves first generic iron sucrose injection for treating iron deficiency anemia in CKD patients aged 2 years and older.

FDA gives approval to Viatris for Iron Sucrose Injection

Iron deficiency anaemia (IDA) is a common complication in chronic kidney disease, and is linked with increased cardiovascular risks and mortality. Viatris’ Iron Sucrose Injection is an intravenous The post FDA gives approval to Viatris for Iron Sucrose Injection appeared first on Pharmaceutical Business review.